A phase I/II trial to investigate the safety and efficacy of rituximab and intravenous immunoglobulin (IVIG) as agents to desensitize highly human leukocyte antigen (HLA) sensitized dialysis patients awaiting kidney transplantation
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Immune globulin (Primary) ; Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 17 Jul 2008 Results have been published in the New England Journal of Medicine.
- 10 Apr 2008 New trial record.